Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Verve Therapeutics, Inc. (VERV)
Company Research
Source: GlobeNewswire
BOSTON , Nov. 01, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today announced that on October 31, 2024, the company granted equity awards to six new employees, pursuant to the company’s 2024 Inducement Stock Incentive Plan, as an inducement material to each new employee entering into employment with the company in accordance with Nasdaq Listing Rule 5635(c)(4). The employees received stock options to purchase an aggregate of 47,600 shares of the company’s common stock and an aggregate of 42,710 restricted stock units (RSUs). The options have an exercise price of $5.73 per share, which is equal to the closing price of the company’s common stock on the date of grant. Each option has a 10-year term and will vest over a period of four years, with 25% of the shares vesting on the one-year anniversary of the grant date and the remainder vesting in equal monthly installments over the follow
Show less
Read more
Impact Snapshot
Event Time:
VERV
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
VERV alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
VERV alerts
High impacting Verve Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
VERV
News
- Verve Therapeutics, Inc. (NASDAQ: VERV) had its price target raised by analysts at Canaccord Genuity Group Inc. from $29.00 to $32.00. They now have a "buy" rating on the stock.MarketBeat
- Verve Therapeutics, Inc. (NASDAQ: VERV) had its price target lowered by analysts at Royal Bank of Canada from $20.00 to $17.00. They now have an "outperform" rating on the stock.MarketBeat
- Verve Therapeutics, Inc. (NASDAQ: VERV) had its price target lowered by analysts at HC Wainwright from $15.00 to $14.00. They now have a "buy" rating on the stock.MarketBeat
- Verve Therapeutics Third Quarter 2024 Earnings: Beats Expectations [Yahoo! Finance]Yahoo! Finance
- Verve Therapeutics Announces Pipeline Progress and Reports Third Quarter 2024 Financial ResultsGlobeNewswire
VERV
Earnings
- 11/5/24 - Beat
VERV
Sec Filings
- 11/18/24 - Form SC
- 11/12/24 - Form SC
- 11/8/24 - Form SC
- VERV's page on the SEC website